One US-made drug treats congenital syphilis, and the country is running short

The U.S. is facing a shortage of Bicillin L-A, the only U.S.-made antibiotic for treating syphilis in pregnant women to prevent congenital syphilis. Pfizer's recall of the drug due to contamination risks has delayed supply until 2027, forcing temporary reliance on imported Lentocilin. The shortage risks worsening infection rates, particularly among Indigenous and Black infants.